125 related articles for article (PubMed ID: 21146145)
1. Cardiovascular events and survival in rheumatoid arthritis: effects of anti-tumor necrosis factor-alpha treatment.
Cugno M
Transl Res; 2011 Jan; 157(1):6-9. PubMed ID: 21146145
[No Abstract] [Full Text] [Related]
2. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
Kaplan MJ
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
[No Abstract] [Full Text] [Related]
3. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
[TBL] [Abstract][Full Text] [Related]
4. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
5. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
6. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour necrosis factor alpha therapy in patients with impaired renal function.
Hueber AJ; Tunc A; Schett G; Manger B
Ann Rheum Dis; 2007 Jul; 66(7):981-2. PubMed ID: 17337474
[No Abstract] [Full Text] [Related]
8. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
[No Abstract] [Full Text] [Related]
9. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
10. [TNF-alpha blockers, rheumatoid arthritis and pulmonary tuberculosis].
Mihăltan F
Pneumologia; 2007; 56(4):212-6. PubMed ID: 18320798
[No Abstract] [Full Text] [Related]
11. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures.
Wendling D; Balblanc JC; Brousse A; Lohse A; Lehuede G; Garbuio P; Toussirot E; Auge B; Jacques D
Ann Rheum Dis; 2005 Sep; 64(9):1378-9. PubMed ID: 16100348
[No Abstract] [Full Text] [Related]
12. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
[No Abstract] [Full Text] [Related]
13. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
14. Infliximab for rheumatoid arthritis in a patient with tuberculosis.
Matsumoto T; Tanaka T; Kawase I
N Engl J Med; 2006 Aug; 355(7):740-1. PubMed ID: 16914717
[No Abstract] [Full Text] [Related]
15. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.
Parke FA; Reveille JD
Arthritis Rheum; 2004 Oct; 51(5):800-4. PubMed ID: 15478165
[TBL] [Abstract][Full Text] [Related]
16. Co-morbidities increase the risk of serious infections in patients with rheumatoid arthritis treated with TNFalpha inhibitors.
Davas EM; Alexiou I; Boulbou M; Koutroumpas A; Makaritsis K; Stathakis N; Sakkas LI
J Infect; 2008 Nov; 57(5):418-20. PubMed ID: 18760485
[No Abstract] [Full Text] [Related]
17. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
Wolfe F; Michaud K
Am J Med; 2004 Mar; 116(5):305-11. PubMed ID: 14984815
[TBL] [Abstract][Full Text] [Related]
18. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis.
Gonzalez-Juanatey C; Llorca J; Garcia-Porrua C; Martin J; Gonzalez-Gay MA
Arthritis Rheum; 2006 Feb; 55(1):150-3. PubMed ID: 16463428
[No Abstract] [Full Text] [Related]
19. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.
Naumann L; Huscher D; Detert J; Spengler M; Burmester GR; Buttgereit F
Ann Rheum Dis; 2009 Dec; 68(12):1934-6. PubMed ID: 19910303
[No Abstract] [Full Text] [Related]
20. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
